1. Qualified Health Claim Petition—Green Tea and Reduced Risk of Cardiovascular Disease (Docket No. 2005Q-0297) Letter of Denial.
2. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006 Sep 13;296(10):1255-65.
3. Zhou ZX, Qiang H, Ma AQ, Chen H, Zhou P. Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006 Apr;31(2):258-62.
4. Naruko T, Ueda M, Ehara S, et al. Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):877-83.
5. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J Cardiol. 2005 Dec 7.
6. Shimada K, Mokuno H, Matsunaga E, et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis. 2004 Jun;174(2):343-7.
7. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004 Apr;53(4):1068-73.
8. Doo YC, Han SJ, Lee JH, et al. Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris. Am J Cardiol. 2004 Mar 1;93(5):554-8.
9. Nordin FG, Hedblad B, Berglund G, Nilsson J. Plasma oxidized LDL: a predictor for acute myocardial infarction? J Intern Med. 2003 Apr;253(4):425-9.
10. Tatsuguchi M, Furutani M, Hinagata J, et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun. 2003 Mar 28;303(1):247-50.
11. Tsai WC, Li YH, Chao TH, Chen JH. Relation between antibody against oxidized low-density lipoprotein and extent of coronary atherosclerosis. J Formos Med Assoc. 2002 Oct;101(10):681-4.
12. Wang TC, Hsu CC, Chin YP, Lin YL. The autoantibody expression against different source of oxidized low density lipoprotein in patients with acute myocardial infarction. Thromb Res. 2002 Aug 15;107(3-4):175-9.
13. Kelishadi R, Nadery GA, Asgary S. Oxidized LDL metabolites with high family risk for premature cardiovascular disease. Indian J Pediatr. 2002 Sep;69(9):755-9.
14. Dotevall A, Hulthe J, Rosengren A, Wiklund O, Wilhelmsen L. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci (Lond). 2001 Nov;101(5):523-31.
15. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001 Apr 17;103(15):1955-60.
16. Mustafa A, Nityanand S, Berglund L, Lithell H, Lefvert AK. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation. 2000 Nov 21;102(21):2576-81.
17. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus. 1998;7 Suppl 2S132-4.
18. Holvoet P, Vanhaecke J, Janssens S, Van de WF, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998 Oct 13;98(15):1487-94.
19. Ryan M, Owens D, Kilbride B, et al. Antibodies to oxidized lipoproteins and their relationship to myocardial infarction. QJM. 1998 Jun;91(6):411-5.
20. Wu R, Nityanand S, Berglund L, et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3159-63.
21. Schumacher M, Eber B, Tatzber F, et al. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic Biol Med. 1995 Jun;18(6):1087-91.
22. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995 Jan 1;91(1):23-7.
23. Hernandez Figueroa TT, Rodriguez-Rodriguez E, Sanchez-Muniz FJ. The green tea, a good choice for cardiovascular disease prevention? Arch Latinoam Nutr. 2004 Dec;54(4):380-94.
24. Neuhaus T, Voit S, Lill G, et al. Platelet aggregation induced by the C-terminal peptide of thrombospondin-1 (4N1-1) is inhibited by epigallocatechin gallate but not by prostaglandin E1. Platelets. 2004 Nov;15(7):455-7.
25. Son DJ, Cho MR, Jin YR, et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids. 2004 Jul;71(1):25-31.
26. Lill G, Voit S, Schror K, Weber AA. Complex effects of different green tea catechins on human platelets. FEBS Lett. 2003 Jul 10;546(2-3):265-70.
27. Deana R, Turetta L, Donella-Deana A, et al. Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists. Thromb Haemost. 2003 May;89(5):866-74.
28. Kang WS, Chung KH, Chung JH, et al. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase. J Cardiovasc Pharmacol. 2001 Dec;38(6):875-84.
29. de Maat MP. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann NY Acad Sci. 2001;936:509-21.
30. Kang WS, Lim IH, Yuk DY, et al. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb Res. 1999 Nov 1;96(3):229-37.
31. Yang JA, Choi JH, Rhee SJ. Effects of green tea catechin on phospholipase A2 activity and antithrombus in streptozotocin diabetic rats. J Nutr Sci Vitaminol (Tokyo). 1999 Jun;45(3):337-46.
32. Sagesaka-Mitane Y, Miwa M, Okada S. Platelet aggregation inhibitors in hot water extract of green tea. Chem Pharm Bull (Tokyo). 1990 Mar;38(3):790-3.
33. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors. 2000;13(1-4):49-54.
34. Kono S, Shinchi K, Wakabayashi K, et al. Relation of green tea consumption to serum lipids and lipoproteins in Japanese men. J Epidemiol. 1996 Sep;6(3):128-33.
35. Garber AK, Binkley NC, Krueger DC, Suttie JW. Comparison of phylloquinone bioavailability from food sources or a supplement in human subjects. J Nutr. 1999 Jun;129(6):1201-3.
36. Berg MJ. The importance of folic acid. J Gend Specif Med. 1999 May-Jun;2(3):24-8.
37. Ferruzzi MG, Schwartz SJ. Thermal degradation of commercial grade sodium copper chlorophyllin. J Agric Food Chem. 2005 Sep 7;53(18):7098-102.
38. van het Hof KH, de Boer BC, Tijburg LB, et al. Carotenoid bioavailability in humans from tomatoes processed in different ways determined from the carotenoid response in the triglyceride-rich lipoprotein fraction of plasma after a single consumption and in plasma after four days of consumption. J Nutr. 2000 May;130(5):1189-96.
39. Henning SM, Niu Y, Lee NH, et al. Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplement. Am J Clin Nutr. 2004 Dec;80(6):1558-64.
40. Seeram NP, Henning SM, Niu Y, et al. Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. J Agric Food Chem. 2006 Mar 8;54(5):1599-603.